Anti-Human IL-23A (p19) (Tildrakizumab) (I-2170-1.0mg)

IL-23 is a member of the IL-12 family of proinflammatory and immunoregulatory cytokines1 and plays a key role in the differentiation and proliferation of type 17 helper T cells (Th17)2. IL- 23 exists as a heterodimer composed of the IL-12p40 subunit and a novel p19 subunit that is shared with IL-393. IL-23 activities lead to the production of Th17-derived pro-inflammatory cytokines IL-17 and IL-221. Additionally, IL-23 possesses potent anti-tumor and anti-metastatic activity in mouse models of cancer, suggesting a potential role for IL-23 in therapeutic treatment of cancer4. IL-23 also contributes to chronic inflammation of immune-mediated diseases including psoriasis and psoriatic arthritis2. Tildrakizumab is a humanized monoclonal antibody that inhibits IL-23 interaction with the IL-23 receptor by selectively binding the IL-23 p19 subunit5,6. Tildrakizumab has been approved for the treatment of plaque psoriasis.